All News

2021,year

ICYMI: 2021 Rheumatology Year in Review

d Jack Cush, MD

For 2022, let's look our top 10 list of advances, game-changers, worries and those better medical practices that evolved during 2021.

Read Article
PsA.Hands_.jpg

ICYMI: Adalimumab Addition vs. Methotrexate Escalation in Psoriatic Arthritis

d Jack Cush, MD

An interesting study in Lancet Rheumatology shows that psoriatic arthritis patients not responding to methotrexate alone can respond after adding or escalating adalimumab on top of methotrexate to reach minimal disease activity (MDA) response. 

Read Article
CSS Storm Cytokine

Rheumatic Associated Macrophage Activation Syndrome

d Jack Cush, MD

Macrophage Activation Syndrome (MAS) is a hyperinflammatory condition that has a significant mortality risk and may arise in patients with rheumatic disease.

Read Article
infusion.biologic.jpg

ICYMI: Drug Survival Differences in RA, PsA, SpA and PsO

d Jack Cush, MD

Drug survival may be the best measure of efficacy and safety. A study of novel therapy durability (survival) in patients with RA, axial spondyloarthritis, PsA, and psoriasis shows that while all these drugs are approved for said conditions, drug survival varies by condition, suggesting an ongoing need for individualized treatment.

Read Article
renal.stone_.LBP_.jpg

ICYMI: Allopurinol Safety in CKD Patients

d Jack Cush, MD

A study in the Annals of Internal Medicine reports chronic kidney disease (CKD) patients can be safely treated with allopurinol without an increased risk of mortality.

Read Article
Allopurinol Safety in CKD Patients A study in the Annals of Internal Medicine reports chronic kidney disease (CKD) patients can be safely treated with allopurinol without an increased risk of mortality. https://t.co/qUQmuZedJq https://t.co/u2Ntjd1oio

Links:

Dr. John Cush RheumNow ( View Tweet)
QD Clinic - Stills (or Not) MAS off of Tocilizumab https://t.co/YGEifF5X8K https://t.co/719RjYzbE3

Links:

Dr. John Cush RheumNow ( View Tweet)
CDC: Immunocompromised account for 12.2% of all COVID-19 hospitalizations, with an increased risk of ICU (aOR=1.26) and death (aOR = 1.34), even if vaccinated (aOR 1.40; aOR = 1.87). In immunocompromised, death rate was not affected by vaccination. https://t.co/PVRnOPb9gX https://t.co/W2S9eb1cOo

Links:

Dr. John Cush RheumNow ( View Tweet)
Here's a reference for the Salmon-pink skin rashes in adult-onset Still's disease; distinctive in color (faint, salmon-pink), distribution (trunk, neck extremities), and evanescence (comes and goes within the same day). These are not static eruptions! https://t.co/BgzyQeiLyW https://t.co/c3aolVfpav

Links:

Dr. John Cush RheumNow ( View Tweet)
Study of 184 #SLE pts shows that major infections in SLE results in a 7 fold increased risk of a major lupus flare. Abst# OP0143 #EULAR2022 #MedTwitter https://t.co/xUkQmwoeni
Dr. John Cush RheumNow ( View Tweet)
Single center comparison of MAS (n 18) to malignancy related mHLH (n = 16). Notable differences seen in platelet (lower in mHLH 29k v 50K), soluble IL-2R (6814 vs 27972), but more hepatomegaly (25% v 0). Less mortality with MAS (22 v 44%, p 0.18) https://t.co/gYdRfxDM2c https://t.co/ekMJfnzElC

Links:

Dr. John Cush RheumNow ( View Tweet)
Getting Real on PMR Dr. David Liew talks polymyalgia rheumatica and how our understanding has evolved over the years. #EULAR2022 https://t.co/DyVCxDVPE7 https://t.co/PF7zqxX7yk

Links:

Dr. John Cush RheumNow ( View Tweet)
IL-18, Iike IL-1, is a produced by activation of the inflammasome. IL-18 is a potential bioimarker for #AOSD, closely linked to Dz activity & could be a Tx target, either as IL-18 binding protein (Tadekinig alfa) or mAb against IL-18 (phase 1b) https://t.co/ex231f27rg https://t.co/tjsra4blBi

Links:

Dr. John Cush RheumNow ( View Tweet)
Babies! Safety and Outcomes Data on Pregnancies #EULAR2022 highlighted several posters on pregnancy, an important subject as most rheumatic diseases afflicts women during their childbearing years. I wanted to share with you the ones that caught my eye... https://t.co/piA1zhGyAA https://t.co/Kb68AGZgA1

Links:

Dr. John Cush RheumNow ( View Tweet)
FDG-PET/CTscans were used in 58 for FUO evaluations. Dx was Rheumatic (44.5%), malignancy (34.5%), or infectious (10.3%). Most prevalent Rheum dx was vasculitis (17%), especially LG vessel vasculitis. FDG PET/CT is a useful FUO pts https://t.co/NEZDB20OXN https://t.co/4123Gh2v2Y

Links:

Dr. John Cush RheumNow ( View Tweet)
Polymyalgia rheumatica immunological puzzle further illustrated Infiltrating macrophages expressing IL-6 and GM-CSF may drive the subacromial bursitis often seen in polymyalgia rheumatica, according to new research presented at #EULAR2022. https://t.co/oa619uNgnB https://t.co/gyNnsMDXGo

Links:

Dr. John Cush RheumNow ( View Tweet)
It's not a museum. It's the new, look, all electronic poster sessions. Rows & rows of 42 inch touch screen monitors on the wall. You can interact with these online monitors, but I was unable to connect to Netflix. https://t.co/0lcYkjFj3D
Dr. John Cush RheumNow ( View Tweet)
Watch: AURORA-2 Two-year Results Voclosporin For Lupus Nephritis https://t.co/UisuOOABxG #EULAR2022 https://t.co/Og8opUJO2h

Links:

Dr. John Cush RheumNow ( View Tweet)
Voclosporin in lupus nephritis - good 3 year continuation data. #EULAR2022 abtr POS 0186 https://t.co/5EKmvIwTpV https://t.co/nh2bNkSp8G

Links:

Dr. John Cush RheumNow ( View Tweet)
Baricitinib fails in 2 phase 3 lupus trials, BRAVE I & II #EULAR2022 abtr POS 0190 https://t.co/44e5NX4V1V
Dr. John Cush RheumNow ( View Tweet)
×